Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG213

—

77343b54-1525-5d71-ac32-8f057a6d4550

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.519
  • INTERFERON_GAMMA_RESPONSE+0.467
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.404
  • HYPOXIA+0.375
  • TNFA_SIGNALING_VIA_NFKB+0.336
  • PANCREAS_BETA_CELLS+0.329
  • HEDGEHOG_SIGNALING+0.328
  • ALLOGRAFT_REJECTION+0.297
  • INFLAMMATORY_RESPONSE+0.292
  • APOPTOSIS+0.264

Top 10 suppressed

  • G2M_CHECKPOINT-0.441
  • OXIDATIVE_PHOSPHORYLATION-0.441
  • E2F_TARGETS-0.404
  • MYC_TARGETS_V2-0.382
  • MYC_TARGETS_V1-0.372
  • MITOTIC_SPINDLE-0.267
  • ADIPOGENESIS-0.219
  • FATTY_ACID_METABOLISM-0.192
  • ANDROGEN_RESPONSE-0.121
  • PI3K_AKT_MTOR_SIGNALING-0.109

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BS_699TN5RN
brain-umap@2
Ganglioglioma—0.852
2MBCProject_3554_T2_RNA
breast-umap@18
—A0.840
320120155.TNBC
breast-umap@18
—D0.838
4SRR8518199
breast-umap@18
—A0.833
5BS_3H71BH6Q
brain-umap@2
Ganglioglioma—0.831
6R194
bladder-landscape@3
——0.829
7BS_W97QQYKQ
brain-umap@2
Ganglioglioma—0.824
8ERR2598314
medullo-epn-umap@date-based
fetalfetal0.822
9ULC0467T_S13
lung-landscapes@6
—cohortSQ10.817
10ERR2208937
melanoma-umap@29
——0.817

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.519Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.467Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.404Inavolisib— uncovered
HYPOXIA0.375Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.336Inavolisib— uncovered
PANCREAS_BETA_CELLS0.329Cobimetinib— uncovered
HEDGEHOG_SIGNALING0.328Inavolisib— uncovered
ALLOGRAFT_REJECTION0.297Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.292Idelalisib— uncovered
APOPTOSIS0.264Idelalisib— uncovered
P53_PATHWAY0.264Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.254Inavolisib— uncovered
MYOGENESIS0.223Inavolisib— uncovered
KRAS_SIGNALING_UP0.216Inavolisib— uncovered
APICAL_JUNCTION0.169Inavolisib— uncovered
APICAL_SURFACE0.152Temsirolimus— uncovered
CHOLESTEROL_HOMEOSTASIS0.122Remibrutinib— uncovered
UV_RESPONSE_DN0.120Inavolisib— uncovered
GLYCOLYSIS0.113Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.106Inavolisib— uncovered